Peptide News Digest

#Partnership

3 stories

Industry · View digest

D&D Pharmatech and LG AI Research Announce Joint AI-Peptide Drug Discovery Partnership; D&D Shares Jump 17%

South Korea's D&D Pharmatech and LG AI Research announced June 17 a joint development agreement for AI-designed next-generation oral peptide drugs. LG AI Research will use its EXAONE Discovery pharmaceutical AI platform, which analyzes disease-causing protein structures to design optimal peptide sequences, while D&D contributes its oral peptide delivery experience and obesity-pipeline programs. D&D's shares closed up 16.59% on the announcement. The deal extends D&D's late-cycle pipeline momentum, following the April 2026 $1.3M Pfizer research contract on oral obesity peptides after Pfizer's Metsera acquisition, and the June ADA showcase of Korean monthly-GLP-1 programs.

Industry · View digest

Alnylam and Inceptive Sign Up to $2 Billion AI-Peptide Discovery Partnership

On June 4, 2026, Alnylam Pharmaceuticals announced a partnership worth up to $2 billion with Inceptive, the AI biotech focused on programmable RNA and peptide medicines, to apply machine learning to peptide discovery. The deal is the second major back-loaded peptide-AI collaboration to land in the same week, following Regeneron's expanded Parabilis tie-up tied to Phase 3 LAG-3 setbacks.